Ajanta Pharma receives US FDA approval for antifungal drug, voriconazole

Ajanta Pharma Limited, a Rs.1,728 crore Mumbai-based specialty pharmaceutical formulation company, announced the receipt of final approval for voriconazole tablets (50mg & 200mg), from the US Food and Drug Administration (FDA). Voriconazole is a triazole antifungal-drugantifungal for treatment of serious invasive fungal infections and the generic version of Vfend.

Voriconazole tablets is part of ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US FDA has granted Ajanta Pharma 10 ANDA final approvals and 2 tentative approvals. An additional 14 ANDAs are under review with FDA.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top